Telix Q2 2026 Revenue US$247M, Strong Momentum and Pipeline Progress

Melbourne (Australia) and Indianapolis, IN (United States) | July 21, 2026

Telix provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026).

Q2 2026 Highlights [1]

Q2 2026 Revenue

Executive Commentary

Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, “We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA [7] imaging portfolio. This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix’s market leadership, built on clinical differentiation, supply chain resilience and commercial execution. During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses. We are tracking in line with the upper end of our FY 2026 revenue guidance and are investing further in R&D to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value.”

Therapeutics Business Unit

Telix continues to progress its industry-leading Therapeutics pipeline, which spans multiple product candidates and disease areas. Q2 2026 highlights include:

Precision Medicine Business Unit

PSMA imaging portfolio:

Telix’s Precision Medicine business continues to expand its commercial reach and support broader patient access to PSMA-PET/CT imaging [17] . Q2 2026 highlights include:

TLX101-Px, (Floretyrosine F 18 or 18F-FET) for brain cancer imaging:

Zircaix ® 21 (TLX250-Px, 89 Zr-DFO-girentuximab) for kidney cancer imaging:

Telix Manufacturing Solutions (TMS): Expanded global operations

TMS continues to expand its global operations which are fundamental to Telix’s future growth, supporting supply chain resilience. Q2 2026 highlights include:

Corporate Updates

Telix entered into a strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies [26] . The strategic partnership combines Telix’s radiopharmaceutical development, manufacturing and supply chain capabilities with Regeneron’s leading antibody discovery and development platforms, creating a framework to advance multiple novel oncology programs and further strengthen Telix’s position in Precision Medicine. On execution of the agreement, Telix has received an initial non-refundable payment from Regeneron of US$40 million.

Telix also completed a refinancing of its existing convertible bond structure, issuing US$600 million of new convertible bonds due 2031 and repurchasing all outstanding 2029 convertible bonds [27] . The transaction extends debt maturities, enhances financial flexibility and further strengthens the Company’s capital structure, supporting the execution of Telix’s long-term growth strategy, including developing its late-stage therapeutics pipeline.

Three new Non-Executive Directors were appointed during the quarter as part of Telix’s Board expansion and succession planning. Effective May 11, 2026, David Gill, Maria Rivas, MD, and William Jellison [28] joined the Board, further strengthening the Board’s clinical, commercial, financial and governance expertise, enhancing the Company’s capabilities as a dual-listed, commercial stage biopharmaceutical company.

FY 2026 guidance

Illuccix® (kit for the preparation of gallium-68 gozetotide injection) is commercially available in 22 countries including the U.S. Gozellix® (kit for the preparation of gallium-68 gozetotide injection) is approved in the U.S. No other Telix product mentioned in this announcement has received a marketing authorization in any jurisdiction.

[1] The financial information for the quarter ended June 30, 2026 is unaudited.

[2] Metastatic castration-resistant prostate cancer.

[3] Telix ASX disclosure July 2, 2026. ClinicalTrials.gov ID: NCT06520345 .

[4] ClinicalTrials.gov ID: NCT07052214 .

[5] Primarily sales of Illuccix and Gozellix in our Precision Medicine business.

[6] Telix Manufacturing Solutions (TMS) third-party revenue predominantly driven by RLS Radiopharmacies (RLS), excludes Illuccix and Gozellix sales and TMS inter-segment revenue.

[7] Prostate-specific membrane antigen.

[8] Telix ASX disclosure July 2, 2026.

[9] Telix LinkedIn June 25, 2026. Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437 .

[10] Telix media release July 16, 2026. Australian New Zealand Clinical Trials Registry ID: ACTRN12626000034336 .

[11] Telix media release July 21, 2026. ClinicalTrials.gov ID: NCT07197580 .

[12] Clear cell renal cell carcinoma.

[13] Telix’s global development program for TLX250-Tx includes the separate LUTEON ATLAS study in the U.S. and Europe.

[14] ClinicalTrials.gov ID: NCT07100730 .

[15] ClinicalTrials.gov ID: NCT05450744 .

[16] Telix media release May 19, 2026.

[17] Imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography.

[18] Emmett et al. Eur Urol. 2021.

[19] Buteau et al. Lancet Oncol. 2026. ClinicalTrials.gov ID: NCT05154162 .

[20] Telix media release July 17, 2026. Japan Registry of Clinical Trials identifier: JRCT2031250473.

[21] Brand name subject to final regulatory approval.

[22] Prescription Drug User Fee Act.

[23] Telix ASX disclosure April 10, 2026.

[24] Telix media release May 1, 2026.

[25] Telix media release July 16, 2026.

[26] Telix ASX disclosure April 13, 2026.

[27] Telix ASX disclosure April 23, 2026.

[28] Telix ASX disclosure April 2, 2026. Telix ASX disclosure April 9, 2026.

The post Telix Q2 2026 Revenue US$247M, Strong Momentum and Pipeline Progress appeared first on Telix Pharmaceuticals .